Keros Therapeutics received approval for rusfertide for polycythemia vera from Protagonist Therapeutics and Takeda.
Public source
Publisher name
Public post
Congratulations to the Protagonist Therapeutics and Takeda teams on the approval of rusfertide for polycythemia vera. This one is particularly meaningful for me. During…
Company
Keros Therapeutics
Keros is dedicated to the discovery and development of novel therapeutics for multiple disorders.
- Industry
- Biotechnology Research
- Location
- Lexington, US
- Company size
- 51–200 employees
About Keros Therapeutics
At Keros, our mission is to innovate therapies that have the potential to shift the treatment paradigm for a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins.
See moreLatest activity
Latest activity from Keros Therapeutics
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
MedChemExpress LLC
MedChemExpress LLC reported that Rusfertide was approved as a hepcidin mimetic for polycythemia vera in August 2026.
Legal & Regulatory
Protagonist Therapeutics
Protagonist Therapeutics received FDA approval for MIMRYLO™, a new medicine developed by Protagonist Therapeutics and Takeda.
Legal & Regulatory
Partnology
Partnology notes that Protagonist Therapeutics and partner Takeda won approval for rusfertide (Mimrylo), the first hepcidin-mimetic peptide cleared for polycythemia vera, giving the rare blood disorder its first therapy of this kind.
Legal & Regulatory
MPN Research Foundation
MPN Research Foundation reported that the FDA has approved Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera.
Legal & Regulatory
PharmaEssentia